CBL-514
- Generic Name
- CBL-514
A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05234736
- Locations
- 🇺🇸
DermResearch Inc, Austin, Texas, United States
A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04699669
- Locations
- 🇦🇺
Investigational site, Melbourne, Australia
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT04698642
- Locations
- 🇦🇺
Investigational site, Melbourne, Australia
A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04575467
- Locations
- 🇦🇺
Investigational Site, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath